ProCE Banner Activity

Optimizing Use of BTK Inhibitors in CLL/SLL and MCL for Managed Care Professionals

Slideset

Download these slides from a live webinar to learn more about the latest data supporting the efficacy and safety of BTK inhibitor–based therapeutic approaches for patients with CLL/SLL or MCL, including strategies to promote equitable, cost-effective, and evidence-based care for patients with these diseases.

Released: January 11, 2024

Share

Faculty

Donald C. Moore

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

Victoria R. Nachar

Victoria R. Nachar, PharmD, BCOP

Clinical Pharmacist Specialist
Hematology
University of Michigan Rogel Cancer Center 
Ann Arbor, MI

Provided by

Provided by ProCE, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly